New drug combo shows promise for AML patients
NCT ID NCT05471700
First seen Oct 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tested a combination of two drugs, azacitidine and venetoclax, in 40 adults aged 45 to 65 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well the treatment worked and how safe it was. Participants received the drugs and were monitored for remission and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital of Southern Medical University
Guanzhou, Guandong, 510250, China
Conditions
Explore the condition pages connected to this study.